<p>大和证券集团在最近向证券交易委员会提交的 13F 表格中披露，第二季度其在 IDEXX Laboratories, Inc.（纳斯达克代码：IDXX - 免费报告）的持股增加了 11.1%。该机构投资者在本季度额外购买了 2,120 股后，持有该公司 21,298 股股票。截至其最近的 SEC 文件，大和证券集团在 IDEXX Laboratories 的持股价值为 11,423,000 美元。</p>
<p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
<ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
<p>其他一些机构投资者也增加或减少了在该公司的股份。Gerber Kawasaki 财富与投资管理在第二季度收购了价值 253,000 美元的 IDEXX Laboratories 新股份。SVB Wealth LLC 在第二季度将其在 IDEXX Laboratories 的持股增加了 5.1%。SVB Wealth LLC 现在拥有 4,333 股该公司的股票，价值 2,324,000 美元，此前在该期间内又购买了 212 股。Crestmont Private Wealth LLC 在第二季度将其在 IDEXX Laboratories 的股份增加了 5.5%。Crestmont Private Wealth LLC 现在拥有 908 股该公司的股票，价值 487,000 美元，此前在上个季度又购买了 47 股。Ossiam 在第二季度将其在 IDEXX Laboratories 的持股增加了 35.2%。Ossiam 现在拥有 6,644 股该公司的股票，价值 3,563,000 美元，此前在该期间内又购买了 1,731 股。最后，加利福尼亚公共雇员退休系统在第二季度将其在 IDEXX Laboratories 的持股增加了 4.7%。加利福尼亚公共雇员退休系统现在拥有 148,408 股该公司的股票，价值 79,597,000 美元，此前在该期间内又购买了 6,706 股。目前 87.84% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级变动</h2>
<p>几位分析师对该公司发布了报告。瑞银集团将 IDEXX Laboratories 的目标价格从 710.00 美元上调至 750.00 美元，并在 11 月 4 日（星期二）的研究报告中给予该公司 “中性” 评级。杰富瑞金融集团重申了 “买入” 评级，并在 11 月 4 日（星期二）的研究报告中对 IDEXX Laboratories 的股票设定了 830.00 美元的目标价格。BTIG 研究将 IDEXX Laboratories 的目标价格从 785.00 美元上调至 830.00 美元，并在 11 月 4 日（星期二）的报告中给予该公司 “买入” 评级。巴克莱在周一开始对 IDEXX Laboratories 的股票进行覆盖。他们给予该股票 “超配” 评级，并设定 850.00 美元的目标价格。最后，摩根士丹利在 11 月 4 日（星期二）的研究报告中将 IDEXX Laboratories 的目标价格从 765.00 美元上调至 805.00 美元，并给予该股票 “超配” 评级。八位投资分析师对该股票给予 “买入” 评级，三位分析师给予该公司股票 “持有” 评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价格为 763.50 美元。</p>
<p><strong>获取我们对 IDEXX Laboratories 的最新分析</strong></p>
<h2>IDEXX Laboratories 的内部活动</h2>
<p>在其他新闻中，执行副总裁 Nimrata Hunt 在 11 月 7 日（星期五）出售了 9,425 股 IDEXX Laboratories 的股票。该股票以 703.34 美元的平均价格出售，总价值为 6,628,979.50 美元。出售完成后，该执行副总裁直接持有 21,149 股该公司的股票，价值约为 14,874,937.66 美元。此次交易使其持股减少了 30.83%。该交易已在向证券交易委员会的文件中披露，相关信息可通过此链接访问。公司内部人士持有该公司 0.98% 的股票。</p>
<h2>IDEXX Laboratories 股票上涨 0.4%</h2>
<p>IDXX 股票在周四开盘价为 701.83 美元。IDEXX Laboratories, Inc.的 52 周低点为 356.14 美元，52 周高点为 769.98 美元。该公司的债务与股本比率为 0.24，流动比率为 1.18，速动比率为 0.87。该股票的市值为 560.4 亿美元，市盈率为 55.66，PEG 比率为 4.17，贝塔值为 1.67。该公司的 50 日移动平均价格为 680.30 美元，200 日移动平均价格为 617.20 美元。</p>
<p>IDEXX Laboratories（纳斯达克代码：IDXX - 获取免费报告）最近于 11 月 3 日（星期一）发布了季度财报。该公司报告季度每股收益为 3.22 美元，超出市场共识预期的 3.14 美元，超出幅度为 0.08 美元。IDEXX Laboratories 的净利润率为 24.65%，股本回报率为 67.78%。该公司本季度的收入为 11.1 亿美元，而市场共识预期为 10.7 亿美元。在去年同期，该公司每股收益为 2.80 美元。与去年同期相比，IDEXX Laboratories 的收入增长了 13.3%。IDEXX Laboratories 已将其 2025 财年的每股收益指导设定为 12.810-13.010 美元。分析师平均预计 IDEXX Laboratories, Inc.在当前年度将发布 11.93 美元的每股收益。</p>
<h2>IDEXX Laboratories 公司简介</h2>
<p>（免费报告）</p>
<p>IDEXX Laboratories, Inc.主要开发、制造和分销产品，服务于非洲、亚太地区、加拿大、欧洲、拉丁美洲及国际市场的伴侣动物兽医、牲畜和家禽、乳制品及水质检测市场。该公司通过三个部门运营：伴侣动物组；水质产品；以及牲畜、家禽和乳制品。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 IDEXX Laboratories</li>
<li>什么使一只股票成为优秀的分红股票？</li>
<li>市场动量：三只有重大突破潜力的股票</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>三个理由说明 Casey’s General Stores 将继续上涨</li>
<li>三只最佳金融科技股票以提升投资组合</li>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
<p><strong>想知道其他对冲基金持有 IDXX 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
<p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 IDEXX Laboratories 并不在名单上。</p>
<p>虽然 IDEXX Laboratories 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IDEXX实验室

<p>大和证券集团在第二季度增持了 IDEXX 实验室 11.1% 的股份，持有 21,298 股，市值为 1142 万美元。分析师们发布了不同的评级，瑞银、杰富瑞、BTIG、巴克莱和摩根士丹利提供的目标价范围在 750 美元到 850 美元之间。IDEXX 的股票开盘价为 701.83 美元，市值为 560.4 亿美元。该公司报告第三季度每股收益为 3.22 美元，超出预期</p>

<p>Daiwa Securities Group Inc. lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,298 shares of the company's stock after buying an additional 2,120 shares during the quarter. Daiwa Securities Group Inc.'s holdings in IDEXX Laboratories were worth $11,423,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>大和证券集团在最近向证券交易委员会提交的 13F 表格中披露，第二季度其在 IDEXX Laboratories, Inc.（纳斯达克代码：IDXX - 免费报告）的持股增加了 11.1%。该机构投资者在本季度额外购买了 2,120 股后，持有该公司 21,298 股股票。截至其最近的 SEC 文件，大和证券集团在 IDEXX Laboratories 的持股价值为 11,423,000 美元。</p>
</div><p>Get <strong>IDEXX Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
</div><p>A number of other institutional investors have also added to or reduced their stakes in the company. Gerber Kawasaki Wealth &amp; Investment Management acquired a new stake in IDEXX Laboratories in the second quarter valued at $253,000. SVB Wealth LLC raised its holdings in shares of IDEXX Laboratories by 5.1% in the 2nd quarter. SVB Wealth LLC now owns 4,333 shares of the company's stock valued at $2,324,000 after purchasing an additional 212 shares during the period. Crestmont Private Wealth LLC lifted its stake in IDEXX Laboratories by 5.5% in the 2nd quarter. Crestmont Private Wealth LLC now owns 908 shares of the company's stock valued at $487,000 after purchasing an additional 47 shares during the last quarter. Ossiam grew its holdings in IDEXX Laboratories by 35.2% during the second quarter. Ossiam now owns 6,644 shares of the company's stock worth $3,563,000 after purchasing an additional 1,731 shares during the period. Finally, California Public Employees Retirement System grew its holdings in IDEXX Laboratories by 4.7% during the second quarter. California Public Employees Retirement System now owns 148,408 shares of the company's stock worth $79,597,000 after purchasing an additional 6,706 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者也增加或减少了在该公司的股份。Gerber Kawasaki 财富与投资管理在第二季度收购了价值 253,000 美元的 IDEXX Laboratories 新股份。SVB Wealth LLC 在第二季度将其在 IDEXX Laboratories 的持股增加了 5.1%。SVB Wealth LLC 现在拥有 4,333 股该公司的股票，价值 2,324,000 美元，此前在该期间内又购买了 212 股。Crestmont Private Wealth LLC 在第二季度将其在 IDEXX Laboratories 的股份增加了 5.5%。Crestmont Private Wealth LLC 现在拥有 908 股该公司的股票，价值 487,000 美元，此前在上个季度又购买了 47 股。Ossiam 在第二季度将其在 IDEXX Laboratories 的持股增加了 35.2%。Ossiam 现在拥有 6,644 股该公司的股票，价值 3,563,000 美元，此前在该期间内又购买了 1,731 股。最后，加利福尼亚公共雇员退休系统在第二季度将其在 IDEXX Laboratories 的持股增加了 4.7%。加利福尼亚公共雇员退休系统现在拥有 148,408 股该公司的股票，价值 79,597,000 美元，此前在该期间内又购买了 6,706 股。目前 87.84% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have issued reports on the company. UBS Group upped their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the company a &#34;neutral&#34; rating in a research note on Tuesday, November 4th. Jefferies Financial Group restated a &#34;buy&#34; rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. BTIG Research raised their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 4th. Barclays started coverage on shares of IDEXX Laboratories in a report on Monday. They issued an &#34;overweight&#34; rating and a $850.00 price objective on the stock. Finally, Morgan Stanley raised their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $763.50.</p>
<div class="lb-trans"><p>几位分析师对该公司发布了报告。瑞银集团将 IDEXX Laboratories 的目标价格从 710.00 美元上调至 750.00 美元，并在 11 月 4 日（星期二）的研究报告中给予该公司 “中性” 评级。杰富瑞金融集团重申了 “买入” 评级，并在 11 月 4 日（星期二）的研究报告中对 IDEXX Laboratories 的股票设定了 830.00 美元的目标价格。BTIG 研究将 IDEXX Laboratories 的目标价格从 785.00 美元上调至 830.00 美元，并在 11 月 4 日（星期二）的报告中给予该公司 “买入” 评级。巴克莱在周一开始对 IDEXX Laboratories 的股票进行覆盖。他们给予该股票 “超配” 评级，并设定 850.00 美元的目标价格。最后，摩根士丹利在 11 月 4 日（星期二）的研究报告中将 IDEXX Laboratories 的目标价格从 765.00 美元上调至 805.00 美元，并给予该股票 “超配” 评级。八位投资分析师对该股票给予 “买入” 评级，三位分析师给予该公司股票 “持有” 评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价格为 763.50 美元。</p>
</div><p><strong>Get Our Latest Analysis on IDEXX Laboratories</strong></p>
<div class="lb-trans"><p><strong>获取我们对 IDEXX Laboratories 的最新分析</strong></p>
</div><h2>Insider Activity at IDEXX Laboratories</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 的内部活动</h2>
</div><p>In other news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Corporate insiders own 0.98% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Nimrata Hunt 在 11 月 7 日（星期五）出售了 9,425 股 IDEXX Laboratories 的股票。该股票以 703.34 美元的平均价格出售，总价值为 6,628,979.50 美元。出售完成后，该执行副总裁直接持有 21,149 股该公司的股票，价值约为 14,874,937.66 美元。此次交易使其持股减少了 30.83%。该交易已在向证券交易委员会的文件中披露，相关信息可通过此链接访问。公司内部人士持有该公司 0.98% 的股票。</p>
</div><h2>IDEXX Laboratories Stock Up 0.4%</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 股票上涨 0.4%</h2>
</div><p>IDXX stock opened at $701.83 on Thursday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The stock has a market capitalization of $56.04 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 4.17 and a beta of 1.67. The business's fifty day moving average price is $680.30 and its two-hundred day moving average price is $617.20.</p>
<div class="lb-trans"><p>IDXX 股票在周四开盘价为 701.83 美元。IDEXX Laboratories, Inc.的 52 周低点为 356.14 美元，52 周高点为 769.98 美元。该公司的债务与股本比率为 0.24，流动比率为 1.18，速动比率为 0.87。该股票的市值为 560.4 亿美元，市盈率为 55.66，PEG 比率为 4.17，贝塔值为 1.67。该公司的 50 日移动平均价格为 680.30 美元，200 日移动平均价格为 617.20 美元。</p>
</div><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company posted $2.80 earnings per share. IDEXX Laboratories's revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.</p>
<div class="lb-trans"><p>IDEXX Laboratories（纳斯达克代码：IDXX - 获取免费报告）最近于 11 月 3 日（星期一）发布了季度财报。该公司报告季度每股收益为 3.22 美元，超出市场共识预期的 3.14 美元，超出幅度为 0.08 美元。IDEXX Laboratories 的净利润率为 24.65%，股本回报率为 67.78%。该公司本季度的收入为 11.1 亿美元，而市场共识预期为 10.7 亿美元。在去年同期，该公司每股收益为 2.80 美元。与去年同期相比，IDEXX Laboratories 的收入增长了 13.3%。IDEXX Laboratories 已将其 2025 财年的每股收益指导设定为 12.810-13.010 美元。分析师平均预计 IDEXX Laboratories, Inc.在当前年度将发布 11.93 美元的每股收益。</p>
</div><h2>IDEXX Laboratories Company Profile</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.</p>
<div class="lb-trans"><p>IDEXX Laboratories, Inc.主要开发、制造和分销产品，服务于非洲、亚太地区、加拿大、欧洲、拉丁美洲及国际市场的伴侣动物兽医、牲畜和家禽、乳制品及水质检测市场。该公司通过三个部门运营：伴侣动物组；水质产品；以及牲畜、家禽和乳制品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than IDEXX Laboratories</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 IDEXX Laboratories</li>
<li>什么使一只股票成为优秀的分红股票？</li>
<li>市场动量：三只有重大突破潜力的股票</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>三个理由说明 Casey’s General Stores 将继续上涨</li>
<li>三只最佳金融科技股票以提升投资组合</li>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding IDXX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对冲基金持有 IDXX 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IDXX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
</div><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 IDEXX Laboratories 并不在名单上。</p>
</div><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IDEXX Laboratories 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

大和证券集团公司购买了 IDEXX 实验室公司 2,120 股股票，股票代码为$IDXX